{"hands_on_practices": [{"introduction": "To truly understand a signaling pathway, we must be able to measure its activity. This exercise challenges you to think like an experimental biologist designing a Western blot, a fundamental technique for detecting specific proteins. Your task is to select the necessary tools to distinguish between the mere presence of a protein and its active, signaling state, which is the key to confirming pathway activation [@problem_id:2344155].", "problem": "A cell biologist is investigating the effects of a newly discovered growth factor, called Mitogenin, on a line of cultured fibroblasts. The biologist hypothesizes that Mitogenin promotes cell proliferation by activating the Phosphoinositide 3-kinase (PI3K)-Akt signaling pathway. In this pathway, the binding of a growth factor to its receptor on the cell surface leads to the activation of the enzyme PI3K. Activated PI3K then catalyzes the phosphorylation of a lipid in the plasma membrane, which in turn recruits and leads to the phosphorylation and activation of the serine/threonine-specific protein kinase, Akt (also known as Protein Kinase B). This activated, phosphorylated form of Akt (p-Akt) is the key signaling molecule that carries the signal downstream to effect cellular responses like proliferation and survival.\n\nTo test this hypothesis, the biologist prepares protein lysates from two populations of fibroblasts: a control group (untreated) and an experimental group (treated with Mitogenin for 30 minutes). They plan to analyze these lysates using a technique called Western blotting, which separates proteins by size and allows for the detection of specific proteins using antibodies.\n\nWhich of the following sets of primary antibodies would provide the most direct and conclusive evidence to support the hypothesis that Mitogenin activates the PI3K-Akt pathway?\n\nA. Antibodies against total PI3K and total Akt.\n\nB. Antibodies against the Mitogenin receptor and total PI3K.\n\nC. Antibodies against phosphorylated Akt (p-Akt), total Akt (t-Akt), and Î²-actin.\n\nD. An antibody against only phosphorylated Akt (p-Akt).\n\nE. Antibodies against phosphorylated ERK (p-ERK) and total ERK (t-ERK).", "solution": "The hypothesis is that Mitogenin activates the PI3K-Akt pathway. A direct biochemical readout of Akt activation is its phosphorylation at regulatory residues, which can be detected by phospho-specific antibodies in a Western blot. Therefore, the key measurable change expected upon Mitogenin treatment is an increase in phosphorylated Akt (p-Akt), while the total amount of Akt (t-Akt) should be used to normalize for Akt protein abundance, and a housekeeping protein such as $\\beta\\text{-actin}$ should control for equal protein loading across lanes.\n\nIn Western blot analysis, the most direct and conclusive evidence of pathway activation is an increase in the normalized phosphorylation state of Akt in treated versus control samples, which can be expressed as an increase in the ratio\n$$\n\\frac{\\text{p-Akt}}{\\text{t-Akt}}\n$$\nin the Mitogenin-treated lysate relative to the untreated control, with comparable $\\beta\\text{-actin}$ signal indicating equal loading.\n\nEvaluation of options:\n- Option A (total PI3K and total Akt) measures protein abundance but not activation state; it cannot test whether the pathway is activated.\n- Option B (Mitogenin receptor and total PI3K) assesses receptor presence and PI3K abundance, not PI3K activity or downstream Akt activation; it is not a direct test of pathway activation.\n- Option C (p-Akt, t-Akt, and $\\beta\\text{-actin}$) provides a phospho-specific readout of Akt activation, normalization to total Akt, and a loading control, enabling a conclusive determination that Mitogenin increases Akt activation.\n- Option D (only p-Akt) lacks controls for total Akt amount and total protein loading; any observed change could be confounded by variable loading or changes in total Akt levels, making it less conclusive.\n- Option E (p-ERK and t-ERK) interrogates the MAPK/ERK pathway, which is not the pathway in the hypothesis, so it is not a direct test of PI3K-Akt activation.\n\nTherefore, the set of antibodies that most directly and conclusively supports the hypothesis is p-Akt, t-Akt, and $\\beta\\text{-actin}$.", "answer": "$$\\boxed{C}$$", "id": "2344155"}, {"introduction": "A deep understanding of the PI3K-Akt pathway has direct applications in medicine, particularly in developing cancer therapies. This problem presents a common scenario in drug discovery, where a specific inhibitor is used to block a key enzyme in a disease-driving pathway. By working through this thought experiment, you will practice predicting the downstream cellular consequences of targeted inhibition, a crucial skill in modern pharmacology [@problem_id:2344175].", "problem": "The Phosphoinositide 3-kinase (PI3K)-Akt signaling pathway is a critical regulator of cell growth, survival, and proliferation. In a typical activation sequence, a growth factor binds to a receptor tyrosine kinase (RTK) on the cell surface, leading to the recruitment and activation of PI3K. Activated PI3K then catalyzes the phosphorylation of phosphatidylinositol (4,5)-bisphosphate ($PIP_2$) to generate phosphatidylinositol (3,4,5)-trisphosphate ($PIP_3$). $PIP_3$ acts as a second messenger, recruiting the protein kinase Akt (also known as Protein Kinase B) to the plasma membrane, where it becomes phosphorylated and fully activated. Activated Akt, in turn, phosphorylates a variety of downstream target proteins that collectively promote cell cycle progression and inhibit apoptosis (programmed cell death).\n\nIn many forms of breast cancer, this pathway is constitutively active, driving uncontrolled cell proliferation. A research team is testing a new therapeutic agent, which is a highly specific inhibitor of the catalytic activity of PI3K. This drug prevents PI3K from phosphorylating its substrates but does not affect the total amount of PI3K protein in the cell.\n\nAssuming this drug is administered to a culture of breast cancer cells that are dependent on the PI3K-Akt pathway for their growth, which of the following outcomes is the most direct and expected consequence of the treatment?\n\nA. The concentration of $PIP_3$ at the plasma membrane will increase, leading to hyper-activation of Akt and increased cell proliferation.\n\nB. The phosphorylation level of Akt will decrease, leading to a decrease in cell proliferation.\n\nC. The phosphorylation level of Akt will decrease, but cell proliferation will increase due to a compensatory signaling pathway.\n\nD. The total amount of PI3K protein in the cell will decrease, leading to an increase in apoptosis.\n\nE. The total amount of Akt protein will decrease, but its phosphorylation level will increase, leading to no net change in cell proliferation.", "solution": "We consider the canonical sequence: ligand-bound RTK activates PI3K; active PI3K catalyzes phosphorylation of $PIP_2$ to $PIP_3$; $PIP_3$ recruits Akt via its PH domain to the plasma membrane; membrane-localized Akt is phosphorylated by PDK1 and mTORC2 to become active; active Akt promotes cell cycle progression and inhibits apoptosis.\n\nIntroduce the PI3K catalytic inhibitor that prevents substrate phosphorylation but does not change total PI3K protein abundance. Denote the catalytic step by a rate law\n$$\nv_{\\text{PI3K}}=k_{\\text{cat}}[\\text{PI3K}_{\\text{act}}][\\text{PIP}_2],\n$$\nwhere $k_{\\text{cat}}$ is the catalytic constant. A highly specific catalytic inhibitor effectively reduces the catalytic capacity, modeled as a reduction in $k_{\\text{cat}}$ toward zero without changing $[\\text{PI3K}]$. Therefore, the production rate of $PIP_3$ decreases:\n$$\n\\frac{d[\\text{PIP}_3]}{dt}=v_{\\text{PI3K}}-v_{\\text{PIP3\\,dephos}} \\quad \\text{decreases due to reduced } v_{\\text{PI3K}}.\n$$\nAt steady state, the balance shifts to a lower $[\\text{PIP}_3]$ because phosphatases (for example, PTEN) continue to dephosphorylate $PIP_3$ while its synthesis is impaired.\n\nAkt recruitment to the membrane depends on $[\\text{PIP}_3]$ via PH-domain binding, so $[\\text{Akt}_{\\text{mem}}]$ decreases as $[\\text{PIP}_3]$ decreases. The phosphorylation rate of Akt by PDK1 and mTORC2 can be written as\n$$\nv_{\\text{AktP}}=k_{\\text{PDK1}}[\\text{PDK1}][\\text{Akt}_{\\text{mem}}]+k_{\\text{mTORC2}}[\\text{mTORC2}][\\text{Akt}_{\\text{mem}}],\n$$\nwhich decreases when $[\\text{Akt}_{\\text{mem}}]$ decreases. Hence, the phosphorylation level of Akt decreases.\n\nBecause these breast cancer cells are dependent on the PI3K-Akt pathway for growth, reduced Akt activity diminishes phosphorylation of downstream pro-proliferative and anti-apoptotic targets, leading to decreased cell proliferation and relative increase in apoptotic signaling. This is the most direct and expected consequence of inhibiting PI3K catalysis.\n\nEvaluate the options:\n- A is incorrect: inhibiting PI3K decreases, not increases, $[\\text{PIP}_3]$ and Akt activation.\n- B is correct: Akt phosphorylation decreases, leading to decreased proliferation.\n- C is not the most direct expected outcome; while compensatory pathways can exist, the immediate and direct consequence is reduced Akt phosphorylation with decreased proliferation.\n- D is incorrect: the drug does not reduce PI3K protein abundance.\n- E is incorrect: the drug does not reduce total Akt protein, nor would Akt phosphorylation increase when $PIP_3$ is reduced.\n\nThus, the most direct and expected outcome is a decrease in Akt phosphorylation with decreased cell proliferation.", "answer": "$$\\boxed{B}$$", "id": "2344175"}, {"introduction": "Biological signaling is rarely a simple, one-size-fits-all process; it is highly nuanced and quantitative. This practice moves beyond a linear view of the pathway to explore how different protein isoforms, such as Akt1 and Akt2, can have specialized roles. By calculating the cellular response based on isoform-specific activities, you will see how the cell can fine-tune distinct outputs like survival and metabolism through the same core pathway [@problem_id:2344189].", "problem": "A team of cell biologists is investigating the isoform-specific functions of protein kinase B, also known as Akt, a critical node in cell signaling. The Phosphoinositide 3-kinase (PI3K)/Akt pathway is activated by survival factors and regulates a diverse set of cellular processes, including cell survival and metabolism. The team works with two cell lines: a standard wild-type (WT) line and a genetically modified (GM) line.\n\nIn the WT cells, the two major isoforms, Akt1 and Akt2, are expressed at a protein level ratio of 2:1 (Akt1:Akt2).\nThe GM cell line has been engineered to completely lack the Akt1 isoform (a knockout). Furthermore, in this GM line, the Akt2 isoform is overexpressed, reaching a total protein level that is 2.0 times the *total* combined Akt protein level (Akt1 + Akt2) found in the WT cells.\n\nTo quantify the downstream effects, the team has measured the specific enzymatic activities (turnover numbers, $k_{cat}$) of each purified isoform towards two representative substrates: a pro-survival substrate (PSS) and a metabolic regulatory substrate (MRS). The values are as follows:\n-   Akt1 specific activity towards PSS: $k_{cat,1}^{PSS} = 150$ s$^{-1}$\n-   Akt1 specific activity towards MRS: $k_{cat,1}^{MRS} = 40$ s$^{-1}$\n-   Akt2 specific activity towards PSS: $k_{cat,2}^{PSS} = 65$ s$^{-1}$\n-   Akt2 specific activity towards MRS: $k_{cat,2}^{MRS} = 220$ s$^{-1}$\n\nAssume that upon treatment with a potent survival factor, all available Akt protein in a cell is maximally phosphorylated and activated. The total cellular response for a given pathway (pro-survival or metabolic) is defined as the total rate of phosphorylation of its corresponding substrate (PSS or MRS). This rate is the sum of the contributions from all active Akt isoforms present, where each isoform's contribution is the product of its concentration and its specific activity.\n\nCalculate the dimensionless ratio of the total metabolic response to the total pro-survival response in the genetically modified (GM) cell line after activation. Round your final answer to three significant figures.", "solution": "Let $[A1]$ and $[A2]$ denote the protein concentrations of Akt1 and Akt2, respectively. In wild type (WT) cells, the expression ratio is $[A1]_{\\mathrm{WT}}:[A2]_{\\mathrm{WT}}=2:1$. Let the total WT Akt be $A_{\\mathrm{tot,WT}}=[A1]_{\\mathrm{WT}}+[A2]_{\\mathrm{WT}}$. Then:\n$$\n[A1]_{\\mathrm{WT}}=\\frac{2}{3}A_{\\mathrm{tot,WT}},\\quad [A2]_{\\mathrm{WT}}=\\frac{1}{3}A_{\\mathrm{tot,WT}}.\n$$\nIn the genetically modified (GM) line, $[A1]_{\\mathrm{GM}}=0$ and $[A2]_{\\mathrm{GM}}=2.0\\,A_{\\mathrm{tot,WT}}$ by construction.\n\nUpon maximal activation, the total phosphorylation rate for a given substrate $X$ (either PSS or MRS) equals the sum over isoforms of isoform concentration times its specific activity:\n$v^{X}=\\sum_{i} [\\mathrm{Akt}_{i}]\\,k_{cat,i}^{X}.$\nIn the GM line, only Akt2 contributes, so\n$$\nv_{\\mathrm{GM}}^{\\mathrm{MRS}}=[A2]_{\\mathrm{GM}}\\,k_{cat,2}^{\\mathrm{MRS}},\\quad\nv_{\\mathrm{GM}}^{\\mathrm{PSS}}=[A2]_{\\mathrm{GM}}\\,k_{cat,2}^{\\mathrm{PSS}}.\n$$\nThe requested dimensionless ratio of total metabolic to pro-survival responses in the GM line is therefore\n$$\nR=\\frac{v_{\\mathrm{GM}}^{\\mathrm{MRS}}}{v_{\\mathrm{GM}}^{\\mathrm{PSS}}}\n=\\frac{[A2]_{\\mathrm{GM}}\\,k_{cat,2}^{\\mathrm{MRS}}}{[A2]_{\\mathrm{GM}}\\,k_{cat,2}^{\\mathrm{PSS}}}\n=\\frac{k_{cat,2}^{\\mathrm{MRS}}}{k_{cat,2}^{\\mathrm{PSS}}}.\n$$\nSubstituting the given values $k_{cat,2}^{\\mathrm{MRS}}=220\\,\\mathrm{s}^{-1}$ and $k_{cat,2}^{\\mathrm{PSS}}=65\\,\\mathrm{s}^{-1}$,\n$R=\\frac{220}{65}=\\frac{44}{13}\\approx 3.384615\\ldots$\nRounded to three significant figures, the ratio is $3.38$.", "answer": "$$\\boxed{3.38}$$", "id": "2344189"}]}